Baudax Bio, Inc. (BXRX) News

Baudax Bio, Inc. (BXRX): $3.40

0.12 (+3.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BXRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter BXRX News Items

BXRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest BXRX News From Around the Web

Below are the latest news stories about BAUDAX BIO INC that investors may wish to consider to help them evaluate BXRX as an investment opportunity.

The 7 Most Sold-Off Stocks of 2022

With 2022 rapidly coming to a close, it’s time to take a look back at the most sold-off stocks so you know which names to avoid.

Josh Enomoto on InvestorPlace | December 24, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | December 12, 2022

Dear Boeing (BA) Stock Fans, Mark Your Calendars for a ‘Historic Announcement’ on Dec. 13

Boeing (BA) stock fans will want to keep an eye on the company when Dec. 13 rolls around as it has a "historic announcement" to make.

William White on InvestorPlace | December 9, 2022

Why Is Baudax Bio (BXRX) Stock Up 46% Today?

Baudax Bio (BXRX) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000.

William White on InvestorPlace | December 9, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!

William White on InvestorPlace | December 9, 2022

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. This randomized, double-blind clinical trial will study BX1000 in approximately 80 adult patients, 18-65 years of age, who u

Yahoo | December 8, 2022

Baudax Bio Announces Closing of $5 Million Public Offering

MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of

Yahoo | December 6, 2022

Baudax Bio Announces Pricing of $5 Million Public Offering

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public of

Yahoo | December 2, 2022

Baudax Bio Announces 1-for-40 Reverse Stock Split

MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Company’s Board of Directors has approved a 1-for-40 reverse stock split of its common shares (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on December 1, 2022 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a po

Yahoo | November 30, 2022

Noble Financial Reaffirms Their Buy Rating on Baudax Bio (BXRX)

In a report released today, Gregory Aurand from Noble Financial maintained a Buy rating on Baudax Bio (BXRX - Research Report), with a price target of $0.60. The company's shares closed yesterday at $0.14.Aurand covers the Healthcare sector, focusing on stocks such as Baudax Bio, ChitogenX, and BioSig Technologies. According to TipRanks, Aurand has an average return of -60.9% and a 17.65% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baudax Bio with a $0.60 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $18.86 and a one-year low of $0.13.

Ryan Adist on TipRanks | November 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4885 seconds.